摘要：

The article discusses a study which investigated the blood-pressure-lowering effects of darusentan, a vasodilatory, selective endothelin type A antagonist, in patients with treatment-resistant hypertension. The study, which was undertaken in 117 sites in North and South America, Europe, New Zealand and Australia, has enrolled 379 patients with systolic blood pressure (BP) of 140 millimeters of mercury (mmHg) or more who were taking BP-lowering drugs. Participants in the randomised, double-blind trial reported mean reductions in clinic systolic and diastolic BP of 9/5 mmHG with placebo and 17/10 mmHG with darusentan 50 milligrams (mg). It was also concluded that darusentan provides additional BP reduction in patients who have not attained their treatment goals with three or more drugs.

展开